Fig 2.

Forest plots for awake prone positioning compared with usual care for intubation and mortality in adults with hypoxemic respiratory failure due to covid-19. Six trials assessed intubation at 28 days (six Ehrmann trials), two trials assessed intubation at any time during hospital admission (Johnson, Fralick), three trials assessed intubation at 30 days (Alhazzani, Rosén, Harris), one trial assessed intubation at 14 days (Rampon), and two trials did not specify (Jayakumar, Hashemian). Two trials had no intubation events in both arms and were not included in this analysis (Taylor, Kharat). The quasi-randomized trial (Qian) was not included in this analysis. Six trials assessed mortality at 28 days (five Ehrmann trials, Harris), two trials assessed in-hospital mortality (Johnson, Fralick), two trials assessed mortality during intensive care unit admission (Jayakumar, Hashemian), one trial assessed mortality at 14 days (Rampon), one trial assessed mortality at 30 days (Rosén), and one trial assessed mortality at 60 days (Alhazzani). Three trials had no mortality events in both arms and were not included in this analysis (Ehrmann (Ireland), Taylor, Kharat). The quasi-randomized trial (Qian) was not included in this analysis. APP=awake prone positioning